Protein-mimicking compounds for Lewy Body Dementia
Synthetic protein mimetics as potential therapeutics for Lewy Body Dementia
['FUNDING_OTHER'] · UNIVERSITY OF DENVER (COLORADO SEMINARY) · NIH-11195029
This work is developing small protein-like molecules designed to block the harmful brain protein clumps that drive Lewy Body Dementia.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF DENVER (COLORADO SEMINARY) (nih funded) |
| Locations | 1 site (DENVER, UNITED STATES) |
| Trial ID | NIH-11195029 on ClinicalTrials.gov |
What this research studies
As someone worried about Lewy Body Dementia, this project is creating and improving synthetic molecules called oligopyridylamides (OPs) that mimic protein surfaces to stop alpha-synuclein from clumping. The team has already shown these OPs block clumps in cells, neurons, C. elegans, and mice and that lead compounds can cross the blood-brain barrier without obvious toxicity. Over the next years they will optimize the chemistry and drug-like properties, test dosing and safety, and study effects on Lewy body formation in animal models. The goal is to prepare safe, effective candidates that could move into human trials in the future.
Who could benefit from this research
Good fit: When this program reaches clinical trials, ideal candidates would be people diagnosed with or at high risk for Lewy Body Dementia, though the current grant supports preclinical work rather than patient enrollment.
Not a fit: People with dementias not driven by alpha-synuclein pathology (for example, pure Alzheimer's disease without Lewy bodies) may not benefit from these specific compounds.
Why it matters
Potential benefit: If successful, this work could lead to new medicines that prevent or slow Lewy Body Dementia by stopping alpha-synuclein aggregation.
How similar studies have performed: Related preclinical studies targeting alpha-synuclein have shown promise in lab and animal models, but human trial evidence for this approach remains limited.
Where this research is happening
DENVER, UNITED STATES
- UNIVERSITY OF DENVER (COLORADO SEMINARY) — DENVER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KUMAR, SUNIL — UNIVERSITY OF DENVER (COLORADO SEMINARY)
- Study coordinator: KUMAR, SUNIL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.